Under construction – not a live service
Sign in
WithdrawnNo phase

Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study

Reason given: Withdrawn due to funding issues.

Key facts

Where
New Haven, United StatesSee the site

Where in United States

  • Yale New Haven HospitalNew Haven, United StatesNo longer taking part

Trial details

Who runs it
Yale University
Trial code
NCT04283617
Record updated
16 February 2024
Original description
This study is designed to test if there is a difference in brain glucose transport kinetics in poorly controlled T2DM individuals with short duration and long duration of diabetes, using non-invasive magnetic resonance spectroscopy (MRSI). Also, if these changes are reversible with improved glucose control will be tested. A better understanding of the impact of duration of diabetes on brain glucose transport function may have important implications for understanding the pathophysiology of brain complications in T2DM.Read full original descriptionShow less

This study is designed to test if there is a difference in brain glucose transport kinetics in poorly controlled T2DM individuals with short duration and long duration of diabetes, using non-invasive magnetic resonance spectroscopy (MRSI). Also, if these changes are reversible with improved glucose control will be tested. A better understanding of the impact of duration of diabetes on brain glucose transport function may have important implications for understanding the pathophysiology of brain complications in T2DM.

Inclusion: Type 2 Diabetics with HbA1c > 7.5% with short duration of diabetes <5 years or; Type 2 Diabetics with HbA1c > 7.5% longer duration of diabetes >5 years.

Exclusion: Patients treated with incretin-based therapies; Current or recent steroid use in last 3 months; Illicit drug use; Untreated thyroid disease; Uncontrolled hypertension; Known neurological disorders; Untreated psychiatric disorders; Malignancy; Bleeding disorders; Creatinine > 1.5 mg/dL; Hgb < 10 mg/dL; ALT > 3 X ULN; Smoking; Women: pregnancy, actively seeking pregnancy, or breastfeeding; Inability to enter MRI/MRS (per standard MRI safety guidelines).

ClinicalTrials.gov NCT04283617